VGO-Cs01p for children with CD7+ T-cell leukemia that returned or didn't respond
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-phase trial tests a new treatment called VGO-Cs01p for children and teens whose T-cell leukemia (a cancer of the blood) has come back or hasn't gotten better with standard therapy. The treatment targets a marker called CD7 on the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 18 years old
- Leukemia has come back after treatment or did not respond to initial therapy
- Cancer cells must have a marker called CD7 on more than 80% of them
- Must have had at least one other type of treatment that also didn't work
- Overall health must be good enough (ECOG score 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment called CD7 CAR-T, which uses your own immune cells modified to find and attack cancer cells that have a protein called CD7 on their surface. It's for people with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma that has come back or not responded to standard treatments.
This trial tests a new cell therapy called CD7 CAR-T for children with high-risk T-cell lymphoblastic leukemia or lymphoma who have finished initial chemotherapy and are in remission. It aims to prevent relapse.
This trial tests a personalized therapy where your child's own immune cells are modified to find and destroy cancer cells that carry a specific marker called CD7. It is for children and young adults whose T-cell leukemia or lymphoma has come back or not responded to standard treatments.
This trial tests an experimental treatment using donor immune cells engineered to find and attack cancer cells with the CD7 marker. It is for people whose leukemia (T-ALL/LBL or AML) has come back or not responded to standard treatment.
This trial tests a new type of immune therapy called CAR T-cells (engineered to find and attack a protein called CD19 on leukemia cells) for children whose acute lymphoblastic leukemia has come back or hasn't responded to usual treatments. The goal is to see if these special cells can safely help control the disease.
This trial tests a new cell therapy (BG1805) for children whose acute myeloid leukemia (AML) has returned or not responded to standard treatment. The therapy targets a specific marker on leukemia cells called CLL-1 and aims to help the immune system fight the cancer.
Hear when a new T-ALL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.